Is adjuvant therapy ever warranted in localized neuroblastoma

American Journal of Pediatric Hematology/Oncology

Volumn 22, Issue 5, 2000, Pages 399-402

  Matthay, Katherine K ^a   Stram, Daniel ^a  

^a Univ of California Sch of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INVASION; GENE AMPLIFICATION; GENETICS; HUMAN; INFANT; METASTASIS; NEUROBLASTOMA; ONCOGENE MYC; PATHOLOGY; PROGNOSIS;

GENE AMPLIFICATION; GENES, MYC; HUMANS; INFANT; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEUROBLASTOMA; PROGNOSIS;

EID: 0034268930     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200009000-00002     Document Type: Editorial

References (43)

1. Maris JM, Matthay KK. Molecular biology neuroblastoma. J Clin Oncol 1999; 17:2264-79.
2. Alvarado LS, London NB, Look AT, et al. Natural history and biology stage A neuroblastoma: A Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2000; 22:197-205.
3. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A Children's Cancer Group study. J Clin Oncol 2000; 18:18-26.
4. Nitschke R, Smith EI, Shochat S, et al. Localized neuroblastoma treated by surgery: A Pediatric Oncology Group study. J Clin Oncol 1988; 6:1271-9.
5. De Bernardi B, Conte M, Mancini A, et al. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol 1995; 13:884-93.
6. Evans AE, Silber JH, Shpilsky A, et al. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol 1996; 14:2504-10.
7. Rubie H, Hartmann O, Michon J, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Sociaetae Francaise d'Oncologie Pediatrique. J Clin Oncol 1997; 15:1171-82.
8. Matthay KK, Sather HN, Seeger RC, et al. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989; 7:236-44.
9. Kushner BH, Cheung NK, LaQuaglia MP, et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 1996; 14:373-81.
10. Woods WG, Tuchman M, Robison LL, et al. A population-based study of the usefulness of screening for neuroblastoma [see comments]. Lancet 1996; 348:1682-7.
11. Yamamoto K, Hayashi Y, Hanada R, et al. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. J Clin Oncol 1995; 13:2033-8.
12. Bessho F, Hashizume K, Nakajo T, et al. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J Pediatr 1991; 119:237-41.
13. Suita S, Zaizen Y, Sera Y, et al. Mass screening for neuroblastoma: quo vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu area in Japan. J Pediatr Surg 1996; 31:555-8.
14. Nakagawara A, Zaizen Y, Suita S. Genomic and metabolic aspects of neuroblastomas in children under one year of age. Prog Clin Biol Res 1991; 366:115-25.
15. Takeuchi LA, Hachitanda Y, Woods WG, et al. Screening for neuroblastoma in North America. Preliminary results of a pathology review from the Quebec Project. Cancer 1995; 76:2363-71.
16. Sancho-Garnier H, D'Angio GJ. Report of the 1998 Consensus Conference on neuroblastoma screening. Med Pediatr Oncol 1999; 33:357-9.
17. Yamamoto K, Hanada R, Kikuchi A, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 1998; 16:1265-9.
18. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313:1111-6.
19. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group Study. J Clin Oncol 2000; 18: 1260-8.
20. Bowman LC, Castleberry RP, Cantor A, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst 1997; 89:373-80.
21. Rubie H, Hartmann O, Michon J, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1997; 15:1171-82.
22. Tonini GP, Boni L, Pession A, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J Clin Oncol 1997; 15:85-93.
23. Lorenzana AN, Zielenska M, Thorner P, et al. Heterogeneity of MYCN amplification in a child with stroma-rich neuroblastoma ganglioneuroblastoma. Pediatr Pathol Lab Med 1997; 17:875-83.
24. Shimada H, Stram DO, Chatten J, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995; 87:1470-6.
25. Hann HW, Evans AE, Siegel SE, et al. Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res 1985; 45:2843-8.
26. Fong CT, Dracopoli NC, White PS, et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci USA 1989; 86:3753-7.
27. Maris JM, White PS, Beltinger CP, et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 1995; 55:4664-9.
28. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma [see comments]. N Engl J Med 1996; 334:225-30.
29. Guo C, White PS, Weiss MJ, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999; 18:4948-57.
30. Plantaz D, Mohapatra G, Matthay KK, et al. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol 1997; 150:81-9.
31. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma [see comments]. N Engl J Med 1999; 340:1954-61.
32. Favrot MC, Combaret V, Goillot E, et al. Expression of integrin receptors on 45 clinical neuroblastoma specimens. Int J Cancer 1991; 49:347-55.
33. Combaret V, Gross N, Lasset C, et al. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 1996; 14:25-34.
34. Combaret V, Gross N, Lasset C, et al. Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression. Br J Cancer 1997; 75:1151-5.
35. Hailat N, Keim DR, Melhem RF, et al. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest 1991; 88:341-5.
36. Leone A, Seeger RC, Hong CM, et al. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene 1993; 8:855-65.
37. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alphaVbeta3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157-64.
38. Gladson CL, Hancock S, Arnold MM, et al. Stage-specific expression of integrin alphaVbeta3 in neuroblastic tumors. Am J Pathol 1996; 148:1423-34.
39. Rossino P, Defilippi P, Silengo L, et al. Up-regulation of the integrin alpha 1/beta 1 in human neuroblastoma cells differentiated by retinoic acid: correlation with increased neurite outgrowth response to laminin. Cell Regul 1991; 2:1021-33.
40. Yoshihara T, Hibi S, Tsunamoto K, et al. Increased levels of alpha V-associated integrins in association with growth inhibition of cultured tumor cells by bromodeoxyuridine. Anticancer Res 1997; 17:833-8.
41. Soldi R, Mitola S, Strasly M, et al. Role of alphaVbeta3 integrin in the actigation of vascular endothelial growth factor receptor-2. EMBO J 1999; 18:882-92.
42. Sugiura Y, Shimada H, Seeger RC, et al. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res 1998; 58:2209-16.
43. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341:1165-73.